2025 CPT code 0207U
(Active) Effective Date: N/A Revision Date: N/A Deletion Date: N/A Laboratory - Neurology Proprietary Laboratory Analyses Feed
Quantitative imaging of phosphorylated ERK1 and ERK2 in cultured skin fibroblasts to assess Alzheimer's disease probability; add-on code to 0206U.
Modifiers may be applicable depending on the circumstances of service.Consult payer guidelines for specific modifier usage.
Medical necessity for this test would be established by clinical suspicion of Alzheimer’s disease.The test provides an additional layer of diagnostic information beyond standard clinical evaluations. The decision to order this test must be supported by the patient's clinical presentation, history and other relevant information.
The clinical responsibility involves ordering the test based on clinical suspicion of Alzheimer's disease and interpreting the results in conjunction with other clinical findings to inform diagnosis and management.
In simple words: This lab test uses a small skin sample to check for Alzheimer's disease.It measures specific proteins to give a probability score of whether someone has the disease. This test is only used along with another test (0206U).
This CPT code, 0207U, reports quantitative imaging of phosphorylated ERK1 and ERK2 enzymes in response to bradykinin treatment using in situ immunofluorescence.The analysis is performed on cultured skin fibroblasts and is reported as a probability index for Alzheimer's disease. This is an add-on code and must be reported in conjunction with code 0206U.The procedure includes analysis of test results to generate a probability index for Alzheimer's disease.
Example 1: A patient presents with cognitive decline and memory loss.The physician orders both 0206U and 0207U to help assess the likelihood of Alzheimer's disease. The results are used alongside clinical examination, cognitive testing, and other diagnostic investigations., A patient with a family history of Alzheimer's disease undergoes genetic testing, which shows an increased risk.The physician orders 0206U and 0207U as part of a comprehensive evaluation to determine the patient’s current disease status., A research study is evaluating the effectiveness of a new Alzheimer's drug. Researchers use 0206U and 0207U to monitor disease progression in participants receiving the drug compared to a control group.
* Patient demographics and identifying information* Physician's order for the test, including clinical indication for ordering the tests* Complete medical history of the patient, including family history of Alzheimer's disease and other neurological conditions* Results of 0206U and 0207U tests* Relevant clinical notes documenting the patient's cognitive function, including results from cognitive testing* Any other relevant diagnostic tests (e.g., neuroimaging)
** This code is for the Discern™ test by NeuroDiagnostics.The test is reported as a probability index and is not a definitive diagnosis.Always check the latest CPT codebook for updates.
- Revenue Code: Z2 (Undefined Codes)
- RVU: Information not available. RVUs will vary by payer and location.
- Global Days: Not applicable. This is a laboratory test.
- Payment Status: Active
- Modifier TC rule: Not applicable. This is a lab test.
- Fee Schedule: Information not available.Fee schedules are determined by payers and may vary significantly.
- Specialties:Neurology, Geriatric Medicine
- Place of Service:Office, Hospital Outpatient, Clinical Laboratory